Advertisement
Document › Details
Shimadzu Corporation. (4/27/17). "Press Release: New Method for Early Screening of Colorectal Cancer".
Region | Japan | |
Organisation | Shimadzu Corporation | |
Group | Shimadzu (Group) | |
Organisation 2 | Kobe University | |
Product | cancer test, early detection | |
Product 2 | GC/MS (gas chromatography/mass spectrometry) | |
Person | Yoshida, Masaru (Kobe Univ 201704 Associate Professor Graduate School of Medicine) | |
Person 2 | Ojima, Norijyuki (Shimadzu 201704 Manager of Analytical + Measuring Instruments Division) | |
A highly sensitive method that can detect even the earlier stages of colorectal cancer has been developed by researchers in Japan. Shimadzu Corporation, the Kobe University Graduate School of Medicine, and the National Cancer Center in Japan have collaborated to develop a new screening method that comprehensively analyzes the metabolites in our blood. The results of this research were published in the online edition of Oncotarget, a U.S. scientific publication, on February 4, 2017.
Colorectal cancer is one of the most common causes of cancer death, and cases of this cancer are increasing in developed countries. In 2012, a group headed by Associate Professor YOSHIDA Masaru at Kobe University used gas chromatography-mass spectrometry (GC/MS) and clinical metabolomic analysis methods to analyze serum samples from colorectal cancer patients and healthy subjects. The group succeeded in identifying four metabolite markers that can be used to diagnose colorectal cancer and developed a highly reliable diagnostic prediction model using those markers. This model was considered to be more practical in comparison with existing tumor markers, but it lacked sensitivity and specificity when actually used as a screening method.
Following this, a research team combining members from Shimadzu Corporation and Kobe University developed an analytical approach that enabled much more accurate measurement of metabolites in blood plasma. To achieve this, they used high-speed and high-sensitivity GC-MS/MS, which relies on Shimadzu's Advanced Scanning Speed Protocol (ASSP) and Smart MRM technologies.
By using this approach to analyze a large number of samples (at least 600) with known clinical data stored at the National Cancer Center, they were able to develop a high-performance screening method. After reviewing the results of comprehensive analyses of the metabolites contained in blood plasma from colorectal cancer patients and healthy subjects, they discovered eight multi-biomarkers that can be used to diagnose colorectal cancer.
Based on the data for these eight metabolites, they were able to create a diagnostic prediction model for colorectal cancer that exceeded 96% for both sensitivity and specificity. They also confirmed that the sensitivity of this new model remained at high levels even with early-stage colorectal cancer patients (stage 0 and stage I).
This research was conducted with support by the following grant program of the Japan Agency for Medical Research and Development (AMED):
Medical Research and Development Programs Focused on Technology Transfer (SENTAN) (Development theme: Practical implementation of a fully automatic screening system for very early stage diagnosis of colorectal cancer)
Team leader: Noriyuki Ojima, Manager of Analytical & Measuring Instruments Division, Shimadzu Corporation
Sub-leader: Masaru Yoshida, Associate Professor, Kobe University Graduate School of Medicine
> Selected in FY 2013 by the Japan Science and Technology Agency (JST) as a JST-SENTAN Program (Development of Advanced Measurement and Analysis Systems), and transferred to an AMED program in April 2015.
Paper Information
Paper
Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry
Authors
Shin Nishiumi*, Takashi Kobayashi*, Shuichi Kawana, Yumi Unno, Takero Sakai, Koji Okamoto, Yasuhide Yamada, Kazuki Sudo, Taiki Yamaji, Yutaka Saito, Yukihide Kanemitsu, Natsuko Tsuda Okita, Hiroshi Saito, Shoichiro Tsugane, Takeshi Azuma, Noriyuki Ojima, Masaru Yoshida
(*,contributed equally to this study and shared authorship)
Journal
Oncotarget Advanced Publications 2017
DOI:10.18632/oncotarget.15081
Record changed: 2023-06-05 |
Advertisement
More documents for Shimadzu (Group)
- [1] Shimadzu Corporation. (1/24/22). "Press Release: MALDI-8030 – Shimadzu Adds further Versatility to Existing Class-leading Line Up of MALDI-TOF Mass Spectrometers"....
- [2] Shimadzu Corporation. (1/11/19). "Press Release: New Probe Electrospray Ionization Mass Spectrometer Enables Quick Detection of Pharmacological Agents and Metabolites"....
- [3] Shimadzu Corporation. (1/11/19). "Press Release: Shimadzu’s New Preparative Purification LC System Provides High Efficiency, Saves Space, and Enables Multi-Sample Processing"....
- [4] Shimadzu Corporation. (1/9/19). "Press Release: Automating the Analysis of Biological Samples to Provide a Revolutionary Workflow. Shimadzu’s New CLAM-2030 Fully Automated Preparation Module for LCMS"....
- [5] Shimadzu Corporation. (9/5/18). "Press Release: Shimadzu’s New Three Gas Chromatograph Mass Spectrometer Models—GCMS NX Series Achieving World Class Performance and Reforming Working Practices"....
- [6] Shimadzu Corporation. (8/22/18). "Press Release: New ImageReveal MS Mass Spectrometry Imaging Data Analysis Software Simplifies Analysis of Large Quantities of Data"....
- [7] Shimadzu Corporation. (8/7/18). "Press Release: Operating Results and Financial Position (for the Three Months Ended June 30, 2018)". Kyoto....
- [8] Shimadzu Corporation. (7/25/18). "Presentation: Outline & Strategy of Mass Spectrometry Business – Mass Spectrometer Business Presentation Materials (Hiroto Itoi) [Date on Presentation Slide July 3, 2018]"....
- [9] Premier Biosoft International. (6/4/18). "Press Release: Shimadzu Corporation Collaborates with Premier Biosoft to Launch the LCMS-9030 Q-TOF Platform for Comprehensive Lipid and Glycan Analysis". Palo Alto, CA....
- [10] Shimadzu Corporation. (5/10/18). "Press Release: Operating Results and Financial Position (for the Fiscal Year Ended March 31, 2018)". Kyoto....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top